Funding

New Funding Opportunities

Notice Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRCs) (U54 Clinical Trial Optional)
Notice Number RFA-NS-24-022
Post Date April 4, 2023
Expiration Date June 16, 2023
Notice Understanding Neurological Effects of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection (R01 Clinical Trial Optional)
Notice Number RFA-NS-23-021
Post Date March 29, 2023
Expiration Date February 3, 2024
Notice Understanding Neurological Effects of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection (R21 Clinical Trial Optional)
Notice Number RFA-NS-23-022
Post Date March 29, 2023
Expiration Date February 3, 2024
Notice Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R01 Clinical Trials Not Allowed)
Notice Number PAR-20-165
Post Date April 13, 2020
Expiration Date March 6, 2023
Notice Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R21 Clinical Trial Not Allowed)
Notice Number PAR-20-168
Post Date April 13, 2020
Expiration Date May 8, 2023

Past Funding Opportunities

Notice Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRCs) (U54 Basic Experimental Studies Involving Humans Allowed)
Notice Number RFA-NS-22-019
Notice Data Management and Coordinating Center (DMCC) for the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRC) (U24 Basic Experimental Studies with Humans Required)
Notice Number RFA-NS-22-020
Notice Clinical Validation of a Candidate Biomarker for Neurological Disease (U01 Clinical Trial Optional)
Notice Number PAR-18-664
Notice Analytical Validation of a Candidate Biomarker for Neurological Disease (U01 Clinical Trial Optional)
Notice Number PAR-18-550
Notice Analytical Validation of a Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional)
Notice Number PAR-18-549
Notice Clinical Validation of a Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional)
Notice Number PAR-18-548

This page last reviewed on April 13, 2023